Alesia Tietze | Medicinal Chemistry in Cancer | Innovative Research Award

Published on by Global Genetics Award

Innovative Research Award

Alesia Tietze
Affiliation Department of Chemistry and Molecular Biology
Country Sweden
Scopus ID 55193803000
Documents 40
Citations 784
h-index 17
Subject Area Medicinal Chemistry in Cancer
Event Global Genetics Awards
ORCID 0000-0002-9281-548X

Alesia Tietze
Department of Chemistry and Molecular Biology

Alesia Tietze is a researcher affiliated with the Department of Chemistry and Molecular Biology in Sweden, with a research profile identified in the supplied academic information as relating to medicinal chemistry in cancer. The profile is associated with 40 Scopus-indexed documents, 784 citations, and an h-index of 17. These bibliometric indicators provide a quantitative view of research visibility and scholarly impact, while the award assessment itself should be based on the complete research record and independently verified evidence. [3]

Abstract

The Innovative Research Award profile for Alesia Tietze documents a research career represented in the supplied data by an affiliation with the Department of Chemistry and Molecular Biology in Sweden and a subject area of medicinal chemistry in cancer. The associated Scopus record is reported as containing 40 documents, 784 citations, and an h-index of 17. [1] These metrics can be used as supporting indicators of scholarly activity and citation reach, but they do not independently establish the novelty, methodological quality, translational significance, or originality of individual research contributions. The researcher is also associated with an ORCID identifier, providing a persistent identifier for distinguishing the scholarly record. [2]

Keywords

Alesia Tietze; Innovative Research Award; medicinal chemistry; cancer research; chemistry and molecular biology; cancer therapeutics; molecular research; research impact; Scopus; ORCID; Genetics Awards.

Introduction

Medicinal chemistry occupies an interdisciplinary position between chemistry, molecular biology, pharmacology, and therapeutic development. Research in this area may involve the design, synthesis, characterization, optimization, and biological evaluation of compounds intended to address disease-associated molecular targets. In cancer research, medicinal chemistry can intersect with studies of molecular mechanisms, therapeutic targets, biomarkers, drug resistance, and precision-oriented treatment strategies.

Within this broad research environment, academic recognition generally requires consideration of both quantitative and qualitative evidence. Bibliometric indicators such as document counts, citation counts, and h-index values can provide useful measures of scholarly visibility, while publications, methodological contributions, collaborations, and demonstrable scientific outcomes provide additional context. The Genetics Awards program states that submitted research profiles may undergo screening, credential verification, cross-checking of submitted information, and committee review before selection. [3]

Research Profile

The supplied profile identifies Alesia Tietze with the Department of Chemistry and Molecular Biology in Sweden and assigns the subject area of medicinal chemistry in cancer. The reported Scopus information comprises 40 documents, 784 citations, and an h-index of 17. [1] Taken together, these values indicate a documented body of indexed scholarly output and citation activity.

The research profile should be interpreted in relation to the underlying publications rather than as a standalone ranking. Citation indicators can vary according to database coverage, publication type, disciplinary citation practices, author disambiguation, and the date on which the record is consulted. The ORCID identifier supplied for the researcher offers an additional mechanism for connecting scholarly outputs to a persistent researcher identity. [2]

Research Contributions

Based on the supplied subject classification, Tietze’s academic profile is situated within medicinal chemistry in cancer. This field encompasses research that connects chemical science with biological and therapeutic questions relevant to oncology. The precise contribution of an individual researcher should, however, be established from verified publications, research projects, patents, datasets, collaborations, and other primary scholarly evidence rather than inferred solely from a subject-area label.

For an award evaluation, relevant evidence may include the originality of research questions, rigor of experimental or computational methods, reproducibility, significance of findings, contribution to interdisciplinary research, and potential relevance to cancer biology or therapeutic development. The Genetics Awards program identifies research excellence and related scientific contributions among the areas considered within its award framework. [3]

Publications

The supplied Scopus record reports 40 documents associated with the researcher. [1] Because individual publication titles, journals, publication years, authorship positions, and DOI identifiers were not supplied in the source information for this profile, specific publications are not enumerated here. This avoids attributing research findings or bibliographic details that have not been independently established.

For formal award documentation, the publication record can be verified through the researcher’s Scopus author profile and persistent ORCID identifier. Where individual publications are evaluated, DOI metadata should be checked against the publisher or DOI registration record before being included in a nomination dossier.

Research Impact

The supplied bibliometric indicators provide a measurable representation of scholarly impact: 784 citations across 40 reported documents and an h-index of 17. [1] These indicators may support an assessment of sustained research visibility, but they should be interpreted alongside publication quality, contribution to the scientific literature, collaboration, methodological innovation, and the broader significance of the research.

In the context of cancer-focused medicinal chemistry, research impact may also be considered through the extent to which scientific findings contribute to understanding disease mechanisms, identifying therapeutic opportunities, improving molecular tools, or informing subsequent research. Such outcomes require evidence from the underlying scholarly record and should not be inferred solely from citation statistics.

Award Suitability

The supplied profile presents several elements relevant to consideration for an Innovative Research Award: a defined research affiliation, a subject-area focus in medicinal chemistry and cancer, an established indexed publication record, and measurable citation activity. The reported h-index of 17 and 784 citations may serve as supporting bibliometric evidence of scholarly reach. [1]

Final award suitability should remain dependent on the official evaluation process and verification of the nominee’s complete research record. The Genetics Awards program describes a process involving submission screening, verification of credentials, cross-checking of information, committee review, and subsequent selection. [3] Accordingly, the present article should be understood as an academic recognition profile based on the supplied information rather than as an independent declaration of award selection.

Conclusion

Alesia Tietze’s supplied academic profile represents a researcher associated with the Department of Chemistry and Molecular Biology in Sweden and with medicinal chemistry in cancer. The reported Scopus indicators of 40 documents, 784 citations, and an h-index of 17 provide quantitative evidence of an established scholarly record. [1] The associated ORCID identifier further supports persistent scholarly identification. [2]

For the purposes of the Innovative Research Award, these indicators constitute useful supporting evidence but should be considered together with the originality, rigor, significance, and documented outcomes of the researcher’s work. A complete assessment should rely on verified publications and other primary academic evidence in accordance with the award’s stated evaluation procedures. [3]

References

  1. Elsevier. (n.d.). Scopus author details: Alesia Tietze, Author ID 55193803000.

    Scopus.https://www.scopus.com/authid/detail.uri?authorId=55193803000

  2. ORCID. (n.d.). ORCID record: Alesia Tietze, ORCID iD 0000-0002-9281-548X.
    https://orcid.org/0000-0002-9281-548X

  3. Targeted sortase A inhibition by novel peptidomimetic antivirulents against staphylococcal infections

    https://pubmed.ncbi.nlm.nih.gov/41773879/

  4. DNA Scission by Non-Histidine Amino-Terminal Cu(II) and Ni(II) Binding-Like Peptides

    https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.70397

Jacob Raber | Cancer Genetics | Research Excellence Award

Published on by Global Genetics Award

Prof. Jacob Raber | Cancer Genetics | Research Excellence Award

OHSU | United States

Prof. Jacob Raber, Ph.D., is a distinguished Professor with interdisciplinary expertise spanning Behavioral Neuroscience, Neurology, Psychiatry, and Radiation Medicine. He serves as an Affiliated Scientist in the Division of Neuroscience at the Oregon National Primate Research Center (ONPRC), Oregon Health & Science University (OHSU), and holds a courtesy appointment as Professor of Pharmaceutical Sciences at Oregon State University. Dr. Raber earned his BSc in Chemistry and MSc in Pharmacochemistry from the Free University of Amsterdam, where his early research focused on β2-adrenergic receptor desensitization, complemented by training in immunochemistry and Yiddish language and literature. He completed his Ph.D. in Molecular Genetics and Virology at the Weizmann Institute of Science in Israel, investigating interferon-regulated pathways under the mentorship of Dr. Michel Revel. His work integrates molecular genetics with translational neuroscience to advance understanding of brain function and disease.

Citation Metrics (Scopus)

20000
15000
10000
500
0

Citations
15,411

Documents
304

h-index
63

Citations

Documents

h-index


View Scopus Profile
 View Orcid Profile

Featured Publications

Ying Wang | Chromosomal Abnormalities | Best Researcher Award

Published on by Global Genetics Award

Dr. Ying Wang | Chromosomal Abnormalities | Best Researcher Award 

Tongji medical college of huazhong university of science and technology | China

Author Profile

Scopus

【YING WANG: A DEDICATED HEMATOLOGY RESEARCHER】

🎓 EARLY ACADEMIC PURSUITS

Ying Wang’s passion for medicine began at a young age, inspiring her to pursue an extensive medical education. She completed eight years of rigorous training, which included five years of clinical medical study followed by three years specializing in hematology. During this time, she developed a strong interest in laboratory science and hematology technology. Her academic journey allowed her to master fundamental hematological knowledge and acquire essential experimental skills such as polymerase chain reaction (PCR), cell culture, and morphology. This foundation led her to continue her professional journey in the hematology laboratory upon graduation.

💼 PROFESSIONAL ENDEAVORS

Since 2008, Ying Wang has been working in the Hematology Laboratory of Tongji Hospital at Tongji Medical College, Huazhong University of Science and Technology. Her career began with a primary focus on cell morphology, which is the cornerstone of hematopathology. Over three years, she gained an in-depth understanding of the characteristics of different hematological testing methods, including morphology, immunology, cytogenetics, and molecular biology.

For the past seven years, her work has been centered on cytogenetics, particularly in chromosomal analysis and fluorescence in situ hybridization (FISH). Through dedicated training and hands-on practice, she has mastered G-banding chromosomal analysis and developed expertise in applying FISH techniques to malignant blood diseases.

Currently, she leads the Cytogenetics Group, overseeing four team members and ensuring the efficiency and accuracy of daily operations. Under her leadership, her team has successfully established cytogenetic analysis for blood diseases and has processed a significant volume of patient samples. Her contributions to the field are reflected in her authorship of two published research papers.

📝 CONTRIBUTIONS AND RESEARCH FOCUS ON CHROMOSOMAL ABNORMALITIES

Ying Wang’s research focuses on cytogenetic analysis in hematology, particularly in the chromosomal abnormalities associated with blood diseases. Her expertise in G-banding chromosomal analysis and FISH techniques has significantly enhanced diagnostic and prognostic capabilities in hematopathology. She has contributed extensively to the establishment and optimization of cytogenetic methodologies in her laboratory, leading to improved patient diagnoses and treatment strategies.

Despite the labor-intensive nature of cytogenetic analysis, she remains deeply passionate about her work. Knowing that her contributions provide crucial diagnostic and prognostic data to clinicians, she continues to dedicate herself to advancing the field of hematology.

🌟 IMPACT AND INFLUENCE

Ying Wang’s work has had a profound impact on the field of hematology, particularly in China. By pioneering cytogenetic analysis for blood diseases in her laboratory, she has played a critical role in improving diagnostic precision. Her leadership in the Cytogenetics Group has enabled her team to process a high volume of patient samples, ensuring timely and accurate results that guide treatment decisions.

Her research contributions have also influenced the broader scientific community through her publications. Additionally, her involvement as a member of the Hubei Medical Biology and Immunology Society demonstrates her commitment to professional collaboration and knowledge exchange within the field.

📊 ACADEMIC CITATIONS

Ying Wang has authored two peer-reviewed research papers focusing on cytogenetics and blood disease analysis. These publications have contributed to the scientific community’s understanding of chromosomal abnormalities in hematology. Her work continues to be cited by researchers working on similar topics, further solidifying her influence in the field.

💪 LEGACY AND FUTURE CONTRIBUTIONS

As she advances in her career, Ying Wang remains committed to furthering her expertise in hematology and cytogenetics. She acknowledges the limitations of her current knowledge and continuously seeks to expand her skills through further studies and international collaborations. She aspires to stay at the forefront of hematological advancements by engaging with leading laboratories worldwide.

Upon completing her further studies, she aims to implement cutting-edge techniques in her laboratory, thereby enhancing the quality and scope of cytogenetic analysis available to patients in China. Her long-term vision is to contribute to the continued evolution of hematology research and to provide even more precise and valuable diagnostic information for improved patient outcomes.

👨‍🎓 POSITIONS AND HONORS

  • 2008 – Present: Hematology Laboratory, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology (Specialized in Morphology and Cytogenetics).
  • 2017 – Present: Member, Hubei Medical Biology and Immunology Society, China.

📑NOTABLE PUBLICATIONS

"Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation" 

  • Authors: X., Kong, Xin , Z., Xu, Ziyi , Y., Wu, Yanjun , Y., Zhao, Ye , F., Chen, Feng
  • Journal: Journal of Hematology and Oncology
  • Year: 2024

" Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial " 

  • Authors: J., Lu, Jing , H., Qiu, Huiying , Y., Wang, Ying , Y., Zhu, Yu , S., Chen, Suning
  • Journal: Journal of Hematology and Oncology
  • Year: 2024

"CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia" 

  • Authors: Y., Yao, Yao , J., Zhou, Jin , Y., Li, Yanting , D.P., Wu, De Pei , Y., Wang, Ying
  • Journal: Annals of Hematology
  • Year: 2024

"Risk factors for in-hospital mortality in recipients of allogeneic hematopoietic stem cell transplantation with acute respiratory distress syndrome: a retrospective study based on the 2023 new definition of acute respiratory distress syndrome " 

  • Authors: S., Guo, Shiqi , D., Xie, Dan , Y., Gao, Ye , Y., Wang, Ying , Q., Guo, Qiang
  • Journal: BMC Pulmonary Medicine
  • Year: 2024

"A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China " 

  • Authors: Y., Wang, Ying , D.P., Wu, De Pei , X., Zhang, Xiang , Y., Wang, Yu , Y., Zhang, Ying
  • Journal: BMC Medicine
  • Year: 2024

Bin Zhang | Gene Mutation | Best Researcher Award

Published on by Global Genetics Award

Prof Bin Zhang | Gene Mutation | Best Researcher Award

Jining Medical University | China

AUTHOR PROFILE

Scopus

Google Scholar

EARLY ACADEMIC PURSUITS

Bin Zhang's journey into the world of medical research began with a solid foundation in biomedical sciences. His early academic pursuits were marked by a dedication to understanding complex biological systems and a passion for contributing to the field of oncology. This academic dedication led him to become a young expert recognized under the prestigious Taishan Mount Scholars program in China.

PROFESSIONAL ENDEAVORS

In 2018, Bin Zhang was appointed as a researcher at the Affiliated Hospital of Jining Medical University. Here, he established the tumor metabolism research group, assuming the role of Principal Investigator. Under his leadership, the group has grown to focus on four key research directions: the regulatory mechanisms of tumor stem cells, the specificity of tumor biomacromolecules and energy metabolism, the regulation of energy metabolism by oncogenic gene mutations, and the screening of potential drugs targeting tumor metabolism.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE MUTATION

Bin Zhang's research has significantly advanced the understanding of tumor metabolism. His work has been published in esteemed journals such as Cell Reports Medicine, Biomaterials, Oncogene, Journal of Experimental & Clinical Cancer Research, and Stem Cells. These publications highlight his team's investigations into the intricate mechanisms of tumor biology and potential therapeutic targets. The research group delves into how tumor stem cells are regulated, how tumor biomacromolecules function, and how mutations in oncogenes affect energy metabolism, all of which are crucial for developing new cancer treatments.

IMPACT AND INFLUENCE

The impact of Bin Zhang's research is reflected in the high citation rate of his publications, with over 5000 citations to date and an H-Index of 34. His work has not only contributed valuable knowledge to the scientific community but has also influenced ongoing research and development in tumor metabolism. Furthermore, Bin Zhang has successfully secured ten patents, two of which have been transferred, demonstrating the practical applications and commercial potential of his research findings.

ACADEMIC CITES

Bin Zhang is also an active member of the academic community, serving as a reviewer for several high-impact journals including Stem Cells and Development, EBioMedicine, Stem Cell Research & Therapy, Molecular Carcinogenesis, and the Journal of Clinical Laboratory Medicine. His expertise is sought after in evaluating cutting-edge research and ensuring the quality of publications in these journals.

LEGACY AND FUTURE CONTRIBUTIONS

Bin Zhang's legacy in the field of tumor metabolism is marked by his innovative research and commitment to advancing cancer treatment. Currently, he is the principal investigator of two general projects funded by the National Natural Science Foundation of China, two projects funded by Shandong Province, and two projects funded by the Postdoctoral Foundation of China. His ongoing work promises to uncover new insights and develop novel therapies, continuing to push the boundaries of cancer research

NOTABLE PUBLICATIONS

A roadmap from research to clinical testing of mesenchymal stromal cell exosomes in the treatment of psoriasis 2023(7)

IL-13/IL-13RA2 signaling promotes colorectal cancer stem cell tumorigenesis by inducing ubiquitinated degradation of p53 2023(4)

Therapeutic Efficacy of Mesenchymal Stem/Stromal Cell Small Extracellular Vesicles in Alleviating Arthritic Progression by Restoring Macrophage Balance 2023(1)

Engineered EVs with pathogen proteins: promising vaccine alternatives to LNP-mRNA vaccines 2024

Arachidonic acid released by PIK3CA mutant tumor cells triggers malignant transformation of colonic epithelium by inducing chromatin remodeling 2024

Richard Lu | Neurodegenerative Diseases | Best Researcher Award

Published on by Global Genetics Award

Prof Richard Lu | Neurodegenerative Diseases | Best Researcher Award

Cincinnati Children's Hospital Medical Center | United States

Author Profile

Scopus

Early Academic Pursuits

Qing Richard Lu embarked on his academic journey with a Bachelor of Science in Biochemistry from Peking Normal University in Beijing, China, which he completed in 1988. Following this, he pursued a Master of Science in Biophysics at Rutgers University, New Jersey, USA, completing his degree in 1993. He continued his studies at Rutgers University, earning a Ph.D. in Biochemistry in 1997 under the mentorship of Dr. Masayori Inouye.

Professional Endeavors

Dr. Lu's professional career began with a postdoctoral fellowship at the Dana-Farber Cancer Institute, Harvard Medical School, from 1997 to 2002. He worked with Dr. Chuck D. Stiles and collaborated with Dr. David Rowitch. In 2002, he joined the UT Southwestern Medical Center as an Assistant Professor in the Department of Developmental Biology, where he held the position of Southwestern Medical Foundation Endowed Scholar in Medical Research. He was promoted to Associate Professor with tenure in 2009 and continued in this role until 2013. In 2013, Dr. Lu joined Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine. He currently holds the position of Professor with tenure in the Department of Pediatrics. Additionally, he serves as the Scientific Director of the Brain Tumor Center and Program Leader of the Brain Tumor Program in the Division of Experimental Hematology and Cancer Biology, Cancer & Blood Diseases Institute.

Contributions and Research Focus on Neurodegenerative Diseases

Dr. Lu's research primarily focuses on the molecular and cellular mechanisms underlying brain tumors. His work is significant in understanding the biology of brain cancer and developing new therapeutic strategies. He has made notable contributions to the field of experimental hematology and cancer biology through his research on brain tumor development, progression, and treatment.

Impact and Influence

Throughout his career, Dr. Lu has influenced the field of pediatric oncology and neurobiology. His research has provided insights into the genetic and biochemical pathways involved in brain tumors, contributing to the development of novel therapeutic approaches. His work has been recognized through various academic appointments and endowed scholarships, reflecting his significant impact on medical research.

Academic Cites

Dr. Lu's work has been widely published in numerous scientific journals, and his research findings are frequently cited by peers in the field. His publications contribute to the broader scientific understanding of brain tumors and their treatment, solidifying his reputation as a leading expert in the field.

Legacy and Future Contributions

As a leading figure in pediatric oncology and neurobiology, Dr. Lu's legacy is marked by his commitment to advancing scientific knowledge and improving patient outcomes. His ongoing research efforts and leadership roles at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine continue to shape the future of brain tumor research and treatment. Dr. Lu’s future contributions are expected to further enhance the understanding and management of brain tumors, paving the way for innovative therapeutic solutions and improved patient care.

Notable Publications 

Distinct astrocytic modulatory roles in sensory transmission during sleep, wakefulness, and arousal states in freely moving mice 2023(12)

Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability 2023(9)

A road map for the treatment of pediatric diffuse midline glioma 2024(2)

The myelination-associated G protein-coupled receptor 37 is regulated by Zfp488, Nkx2.2, and Sox10 during oligodendrocyte differentiation 2024(1)

BRG1 programs PRC2-complex repression and controls oligodendrocyte differentiation and remyelination 2024

 

Yongqian Shu | Noncoding RNAs and Cancer Development | Excellence in Research

Published on by Global Genetics Award

Prof Dr. Yongqian Shu | Noncoding RNAs and Cancer Development | Excellence in Research

The First Affiliated Hospital of Nanjing Medical University | China

Author Profile 

Orcid ID

Scopus

EARLY ACADEMIC PURSUITS

Shu Yongqian embarked on his academic journey at Suzhou Medical College, where he obtained his Bachelor's degree in Clinical Medicine in 1985. He continued his studies at the same institution, specializing in Pathology for his Master's degree under the supervision of Professor Zhou Zhen. Dr. Yongqian's dedication to his field led him to pursue a PhD in Hematology and Oncology, again at Suzhou Medical College, under the guidance of Professor Ruan Changgeng.

PROFESSIONAL ENDEAVORS

Dr. Yongqian's professional career spans over three decades, marked by significant contributions to the field of medical oncology. He began his clinical practice as a Resident Physician in the Department of Pathology at the Sino-French Friendship Hospital. Over the years, he advanced through various positions, serving as an Attending Physician and later as Deputy Chief Physician in the Oncology Department of the same institution. Currently, he holds the esteemed position of Chief Physician in the Department of Medical Oncology at the First Affiliated Hospital of Nanjing Medical University.

CONTRIBUTIONS AND RESEARCH FOCUS ON NONCODING RNAs AND CANCER DEVELOPMENT

Throughout his career, Dr. Yongqian has demonstrated a steadfast commitment to advancing knowledge in oncology. His research focuses on areas such as hematologic malignancies, solid tumors, and targeted therapies. He has authored numerous papers and contributed significantly to the understanding and treatment of various cancers.

IMPACT AND INFLUENCE

Dr. Yongqian's work has had a profound impact on the field of oncology, both locally and internationally. His research findings have been published in prestigious medical journals, contributing to the collective knowledge base of the medical community. Additionally, his clinical expertise and leadership have earned him the respect of his peers and colleagues.

ACADEMIC CITATIONS

Dr. Yongqian's contributions to the field have been recognized through academic citations, with his work being referenced by fellow researchers and clinicians worldwide. His insights and discoveries continue to shape the landscape of oncology, inspiring future generations of medical professionals.

LEGACY AND FUTURE CONTRIBUTIONS

As a seasoned clinician, researcher, and educator, Dr. Yongqian's legacy extends beyond his individual achievements. He is dedicated to training the next generation of oncologists and fostering collaboration across disciplines to further advance cancer research and patient care. His ongoing commitment to excellence ensures that his impact on the field of oncology will endure for years to come.

Notable Publications

Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation 2020(259)

TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2 2020(98)

KLF5 and MYC modulated LINC00346 contributes to gastric cancer progression through acting as a competing endogeous RNA and indicates poor outcome 2020(22)